Raymond James & Associates’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$21.9K	Sell	6,344 -1,075	-14%	-$5.07K	﹤0.01%	3935
2024 Q2	$37.7K	Sell	7,419 -167	-2%	-$1.25K	﹤0.01%	3823
2024 Q1	$64.3K	Sell	7,586 -133	-2%	-$731	﹤0.01%	3781
2023 Q4	$31.6K	Sell	7,719 -1,472	-16%	-$4.41K	﹤0.01%	3742
2023 Q3	$27.6K	Sell	9,191 -1,783	-16%	-$40.5K	﹤0.01%	3712
2023 Q2	$339K	Sell	10,974 -6	-0.1%	-$249	﹤0.01%	3172
2023 Q1	$544K	Sell	10,980 -3,200	-23%	-$92.8K	﹤0.01%	2872
2022 Q4	$349K	Sell	14,180 -2,140	-13%	-$80K	﹤0.01%	3122
2022 Q3	$1.08M	Buy	16,320 +3,826	+31%	+$192K	﹤0.01%	2344
2022 Q2	$517K	Sell	12,494 -200	-2%	-$9.01K	﹤0.01%	2893
2022 Q1	$640K	Buy	12,694 +60	+0.5%	+$2.94K	﹤0.01%	2912
2021 Q4	$758K	Sell	12,634 -684	-5%	-$33.7K	﹤0.01%	2804
2021 Q3	$659K	Buy	13,318 +2	+0%	+$105	﹤0.01%	2863
2021 Q2	$759K	Buy	13,316 +271	+2%	+$14.5K	﹤0.01%	2777
2021 Q1	$749K	Sell	13,045 -10,089	-44%	-$762K	﹤0.01%	2704
2020 Q4	$1.57M	Buy	23,134 +3,889	+20%	+$530K	﹤0.01%	2048
2020 Q3	$4.88M	Buy	19,245 +2,300	+14%	+$471K	0.01%	1245
2020 Q2	$2.85M	Buy	16,945 +3,548	+26%	+$383K	﹤0.01%	1510
2020 Q1	$932K	Buy	13,397 +5,290	+65%	+$413K	﹤0.01%	2021
2019 Q4	$520K	Buy	8,107 +2,327	+40%	+$135K	﹤0.01%	2708
2019 Q3	$338K	Buy	+5,780	New	+$341K	﹤0.01%	2939